TY - JOUR AU - Singh, J. A. AU - Saag, K. G. AU - Bridges, S. L. AU - Akl, E. A. AU - Bannuru, R. R. AU - Sullivan, M. C. PY - 2016 DA - 2016// TI - 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis JO - Arthritis Care Res. VL - 68 UR - https://doi.org/10.1002/acr.22783 DO - 10.1002/acr.22783 ID - Singh2016 ER - TY - JOUR AU - Smolen, J. S. AU - Landewe, R. AU - Breedveld, F. C. AU - Buch, M. AU - Burmester, G. AU - Dougados, M. PY - 2014 DA - 2014// TI - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204573 DO - 10.1136/annrheumdis-2013-204573 ID - Smolen2014 ER - TY - JOUR AU - Burmester, G. R. AU - Kivitz, A. J. AU - Kupper, H. AU - Arulmani, U. AU - Florentinus, S. AU - Goss, S. L. PY - 2015 DA - 2015// TI - Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial JO - Ann Rheum Dis VL - 74 UR - https://doi.org/10.1136/annrheumdis-2013-204769 DO - 10.1136/annrheumdis-2013-204769 ID - Burmester2015 ER - TY - JOUR AU - Murdaca, G. AU - Spano, F. AU - Contatore, M. AU - Guastalla, A. AU - Penza, E. AU - Magnani, O. PY - 2016 DA - 2016// TI - Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? JO - Expert Opin Drug Saf. VL - 15 UR - https://doi.org/10.1517/14740338.2016.1112375 DO - 10.1517/14740338.2016.1112375 ID - Murdaca2016 ER - TY - CHAP AU - O’Dell, J. R. ED - Stone, J. H. PY - 2016 DA - 2016// TI - Rheumatoid arthritis BT - A clinician’s pearls and myths in rheumatology PB - Springer CY - New York ID - O’Dell2016 ER - TY - JOUR AU - Breedveld, F. C. AU - Weisman, M. H. AU - Kavanaugh, A. F. AU - Cohen, S. B. AU - Pavelka, K. AU - Vollenhoven, R. PY - 2006 DA - 2006// TI - The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment JO - Arthritis Rheum VL - 54 UR - https://doi.org/10.1002/art.21519 DO - 10.1002/art.21519 ID - Breedveld2006 ER - TY - JOUR AU - Klareskog, L. AU - Heijde, D. AU - Jager, J. P. AU - Gough, A. AU - Kalden, J. AU - Malaise, M. PY - 2004 DA - 2004// TI - Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial JO - Lancet VL - 363 UR - https://doi.org/10.1016/S0140-6736(04)15640-7 DO - 10.1016/S0140-6736(04)15640-7 ID - Klareskog2004 ER - TY - JOUR AU - Bykerk, V. P. AU - Ostor, A. J. AU - Alvaro-Gracia, J. AU - Pavelka, K. AU - Román Ivorra, J. A. AU - Graninger, W. PY - 2015 DA - 2015// TI - Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice JO - Clin Rheumatol VL - 34 UR - https://doi.org/10.1007/s10067-014-2857-y DO - 10.1007/s10067-014-2857-y ID - Bykerk2015 ER - TY - JOUR AU - Dougados, M. AU - Kissel, K. AU - Sheeran, T. AU - Tak, P. P. AU - Conaghan, P. G. AU - Mola, E. M. PY - 2013 DA - 2013// TI - Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2 year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY) JO - Ann Rheum Dis VL - 72 UR - https://doi.org/10.1136/annrheumdis-2011-201282 DO - 10.1136/annrheumdis-2011-201282 ID - Dougados2013 ER - TY - STD TI - XELJANZ (tofacitinib) tablets for oral administration. New York, NY: Pfizer Labs; 2012. ID - ref10 ER - TY - JOUR AU - Burmester, G. R. AU - Blanco, R. AU - Charles-Schoeman, C. AU - Wollenhaupt, J. AU - Zerbini, C. AU - Benda, B. PY - 2013 DA - 2013// TI - Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61424-X DO - 10.1016/S0140-6736(12)61424-X ID - Burmester2013 ER - TY - JOUR AU - Kremer, J. AU - Li, Z. G. AU - Hall, S. AU - Fleischmann, R. AU - Genovese, M. AU - Martin-Mola, E. PY - 2013 DA - 2013// TI - Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial JO - Ann Intern Med VL - 159 UR - https://doi.org/10.7326/0003-4819-159-4-201308200-00006 DO - 10.7326/0003-4819-159-4-201308200-00006 ID - Kremer2013 ER - TY - JOUR AU - Heijde, D. AU - Tanaka, Y. AU - Fleischmann, R. AU - Keystone, E. AU - Kremer, J. AU - Zerbini, C. PY - 2013 DA - 2013// TI - Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study JO - Arthritis Rheum VL - 65 UR - https://doi.org/10.1002/art.37816 DO - 10.1002/art.37816 ID - Heijde2013 ER - TY - JOUR AU - Tanaka, Y. AU - Emoto, K. AU - Cai, Z. AU - Aoki, T. AU - Schlichting, D. AU - Rooney, T. PY - 2016 DA - 2016// TI - Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.150613 DO - 10.3899/jrheum.150613 ID - Tanaka2016 ER - TY - JOUR AU - Genovese, M. C. AU - Vollenhoven, R. F. AU - Pacheco-Tena, C. AU - Zhang, Y. AU - Kinnman, N. PY - 2016 DA - 2016// TI - VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis JO - Arthritis Rheumatol. VL - 68 UR - https://doi.org/10.1002/art.39473 DO - 10.1002/art.39473 ID - Genovese2016 ER - TY - JOUR AU - Berg, E. L. AU - Yang, J. AU - Polokoff, M. A. PY - 2013 DA - 2013// TI - Building predictive models for mechanism-of-action classification from phenotypic assay data sets JO - J Biomol Screening. VL - 18 UR - https://doi.org/10.1177/1087057113505324 DO - 10.1177/1087057113505324 ID - Berg2013 ER - TY - JOUR AU - Berg, E. L. AU - Kunkel, E. J. AU - Hytopoulos, E. AU - Plavec, I. PY - 2006 DA - 2006// TI - Characterization of compound mechanisms and secondary activities by BioMAP analysis JO - J Pharmacol Toxicol Methods VL - 53 UR - https://doi.org/10.1016/j.vascn.2005.06.003 DO - 10.1016/j.vascn.2005.06.003 ID - Berg2006 ER - TY - JOUR AU - Ciceri, P. AU - Muller, S. AU - O’Mahony, A. AU - Fedorov, O. AU - Filippakopoulos, P. AU - Hunt, J. P. PY - 2014 DA - 2014// TI - Dual kinase-bromodomain inhibitors for rationally designed polypharmacology JO - Nat Chem Biol VL - 10 UR - https://doi.org/10.1038/nchembio.1471 DO - 10.1038/nchembio.1471 ID - Ciceri2014 ER - TY - JOUR AU - Berg, E. L. AU - Kunkel, E. J. AU - Hytopoulos, E. PY - 2005 DA - 2005// TI - Biological complexity and drug discovery: a practical systems biology approach JO - Syst Biol VL - 152 UR - https://doi.org/10.1049/ip-syb:20050036 DO - 10.1049/ip-syb:20050036 ID - Berg2005 ER - TY - JOUR AU - Kunkel, E. J. AU - Dea, M. AU - Ebens, A. AU - Hytopoulos, E. AU - Melrose, J. AU - Nguyen, D. PY - 2004 DA - 2004// TI - An integrative biology approach for analysis of drug action in models of human vascular inflammation JO - FASEB J. VL - 18 UR - https://doi.org/10.1096/fj.04-1538fje DO - 10.1096/fj.04-1538fje ID - Kunkel2004 ER - TY - JOUR AU - Kunkel, E. J. AU - Plavec, I. AU - Nguyen, D. AU - Melrose, J. AU - Rosler, E. S. AU - Kao, L. T. PY - 2004 DA - 2004// TI - Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models JO - Assay Drug Dev Tech. VL - 2 UR - https://doi.org/10.1089/adt.2004.2.431 DO - 10.1089/adt.2004.2.431 ID - Kunkel2004 ER - TY - JOUR AU - Houck, K. A. AU - Dix, D. J. AU - Judson, R. S. AU - Kavlock, R. J. AU - Yang, J. AU - Berg, E. L. PY - 2009 DA - 2009// TI - Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems JO - J Biomol Screen VL - 14 UR - https://doi.org/10.1177/1087057109345525 DO - 10.1177/1087057109345525 ID - Houck2009 ER - TY - JOUR AU - Xu, D. AU - Kim, Y. AU - Postelnek, J. AU - Vu, M. D. AU - Hu, D. Q. AU - Liao, C. PY - 2012 DA - 2012// TI - RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents JO - J Pharmacol Exp Ther VL - 341 UR - https://doi.org/10.1124/jpet.111.187740 DO - 10.1124/jpet.111.187740 ID - Xu2012 ER - TY - JOUR AU - Bergamini, G. AU - Bell, K. AU - Shimamura, S. AU - Werner, T. AU - Cansfield, A. AU - Müller, K. PY - 2012 DA - 2012// TI - A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation JO - Nat Chem Biol VL - 8 UR - https://doi.org/10.1038/nchembio.957 DO - 10.1038/nchembio.957 ID - Bergamini2012 ER - TY - JOUR AU - Melton, A. C. AU - Melrose, J. AU - Alajoki, L. AU - Privat, S. AU - Cho, H. AU - Brown, N. PY - 2013 DA - 2013// TI - Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation JO - PLoS ONE VL - 8 UR - https://doi.org/10.1371/journal.pone.0058966 DO - 10.1371/journal.pone.0058966 ID - Melton2013 ER - TY - JOUR AU - Berg, E. L. AU - Yang, J. AU - Melrose, J. AU - Nguyen, D. AU - Privat, S. AU - Rosler, E. PY - 2010 DA - 2010// TI - Chemical target and pathway toxicity mechanisms defined in primary human cell systems JO - J Pharmacol Toxicol Methods VL - 61 UR - https://doi.org/10.1016/j.vascn.2009.10.001 DO - 10.1016/j.vascn.2009.10.001 ID - Berg2010 ER - TY - JOUR AU - Scheller, J. AU - Chalaris, A. AU - Schmidt-Arras, D. AU - Rose-John, S. PY - 2011 DA - 2011// TI - The pro- and anti-inflammatory properties of the cytokine interleukin-6 JO - Biochim Biophys Acta VL - 1813 UR - https://doi.org/10.1016/j.bbamcr.2011.01.034 DO - 10.1016/j.bbamcr.2011.01.034 ID - Scheller2011 ER - TY - JOUR AU - Heinrich, P. C. AU - Behrmann, I. AU - Haan, S. AU - Hermanns, H. M. AU - Muller-Newen, G. AU - Schaper, F. PY - 2003 DA - 2003// TI - Principles of interleukin (IL)-6-type cytokine signalling and its regulation JO - Biochem J. VL - 374 UR - https://doi.org/10.1042/bj20030407 DO - 10.1042/bj20030407 ID - Heinrich2003 ER - TY - JOUR AU - Tanaka, T. AU - Kishimoto, T. PY - 2012 DA - 2012// TI - Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases JO - Int J Biol Sci. VL - 8 UR - https://doi.org/10.7150/ijbs.4666 DO - 10.7150/ijbs.4666 ID - Tanaka2012 ER - TY - JOUR AU - Shiozawa, K. AU - Tanaka, Y. AU - Yoshihara, R. AU - Imura, S. AU - Murata, M. AU - Yamane, T. PY - 2005 DA - 2005// TI - Serum levels and pharmacodynamics of methotrexate and its metabolite 7-hydroxy methotrexate in Japanese patients with rheumatoid arthritis treated with 2-mg capsule of methotrexate three times per week JO - Mod Rheumatol VL - 15 UR - https://doi.org/10.3109/s10165-005-0434-6 DO - 10.3109/s10165-005-0434-6 ID - Shiozawa2005 ER - TY - JOUR AU - Thoma, G. AU - Nuninger, F. AU - Falchetto, R. AU - Hermes, E. AU - Tavares, G. A. AU - Vangrevelinghe, E. PY - 2011 DA - 2011// TI - Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family JO - J Med Chem VL - 54 UR - https://doi.org/10.1021/jm101157q DO - 10.1021/jm101157q ID - Thoma2011 ER - TY - JOUR AU - Dymock, B. W. AU - See, C. S. PY - 2013 DA - 2013// TI - Inhibitors of JAK2 and JAK3: an update on the patent literature 2 JO - Expert Opin Ther Patents. VL - 23 UR - https://doi.org/10.1517/13543776.2013.765862 DO - 10.1517/13543776.2013.765862 ID - Dymock2013 ER - TY - JOUR AU - Flanagan, M. E. AU - Blumenkopf, T. A. AU - Brissette, W. H. AU - Brown, M. F. AU - Casavant, J. M. AU - Shang-Poa, C. PY - 2010 DA - 2010// TI - Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection JO - J Med Chem VL - 53 UR - https://doi.org/10.1021/jm1004286 DO - 10.1021/jm1004286 ID - Flanagan2010 ER - TY - JOUR AU - Maini, R. N. AU - Breedveld, F. C. AU - Kalden, J. R. AU - Smolen, J. S. AU - Furst, D. AU - Weisman, M. H. PY - 2004 DA - 2004// TI - Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20159 DO - 10.1002/art.20159 ID - Maini2004 ER - TY - JOUR AU - Gabay, C. AU - Emery, P. AU - Vollenhoven, R. AU - Dikranian, A. AU - Alten, R. AU - Pavelka, K. PY - 2013 DA - 2013// TI - Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(13)60250-0 DO - 10.1016/S0140-6736(13)60250-0 ID - Gabay2013 ER -